Recursion Pharmaceuticals Stock News

Market darlings like Nvidia and Palantir Technologies are still solid investment prospects to be sure. After several years of big gains, however, these crowded trades are starting to show signs of age.

Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the great GPU kingpin Nvidia (NASDAQ:NVDA).

Before market open on Tuesday, Recursion Pharmaceuticals (RXRX -4.74%) published its latest set of quarterly earnings and business update. It might have wished it hadn't, as those quarterly numbers clearly didn't impress the market.

Recursion (RXRX) Q2 Revenue Jumps 33%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Ben R. Taylor - CFO & President of Recursion UK Christopher C.

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)

Recent history has, once again, demonstrated that relatively small biotech companies can see their shares soar significantly on positive developments. Summit Therapeutics' stock is up by more than 2,000% over the past three years, and Abivax, a France-based drugmaker, is up by more than 800% this year following strong clinical data.

Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on August 5, 2025 at...